** Pfizer PFE.N on Tuesday beat Wall Street estimates for fourth-quarter profit driven by cost cuts and steadier COVID vaccine sales
** PFE has been looking to show investors steadier execution and growth after large swings related to its COVID-19 vaccine
OBESITY DATA IS 'LITMUS TEST' FOR PIPELINE
** BMO Capital Markets ("Outperform", PT: $38) says Pfizer continues to execute the plan outlined for investors in what is shaping up to be a manageable macro and political environment
** J.P Morgan ("Neutral", PT: $30) says that while it sees several assets in PFE's pipeline (particularly in oncology) that could make the story more interesting, further progress is necessary to change the narrative on shares
** Guggenheim Partners ("Buy", PT: $33) says data from Pfizer's experimental obesity drug, danuglipron, will be a "litmus test for the company's pipeline productivity"
** Leerink ("Market Perform," PT: $28) says "management is executing well and delivering results above expectations, but we await future pipeline developments"
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.